View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 17, 2019updated 12 Jul 2022 11:59am

Gilead combination therapy for NASH misses Phase II primary goal

Top-line data reported by Gilead Sciences has revealed that the Phase II ATLAS clinical trial of cilofexor, firsocostat and selonsertib did not meet the primary endpoint in nonalcoholic steatohepatitis (NASH) patients with bridging fibrosis (F3) and compensated cirrhosis (F4).

Top-line data reported by Gilead Sciences has revealed that the Phase II Atlas clinical trial of cilofexor, firsocostat and selonsertib did not meet the primary endpoint in nonalcoholic steatohepatitis (NASH) patients with bridging fibrosis (F3) and compensated cirrhosis (F4).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The 48-week randomised, double-blind, placebo-controlled trial assessed the drugs as monotherapy and dual combination regimens in 392 patients.

Each of the drugs exhibits different mechanisms of action. Cilofexor is a nonsteroidal farnesoid X receptor (FXR) agonist, firsocostat is an acetyl-CoA carboxylase (ACC) inhibitor, and selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor.

According to the results, no regimen demonstrated a statistically significant increase in the proportion of participants with a ≥1-stage improvement in fibrosis without worsening of NASH, which was the primary efficacy endpoint of the study.

However, the firsocostat and cilofexor combination led to statistically significant improvements in various fibrosis and liver function measures compared to placebo.

In the trial, the selonsertib monotherapy group was discontinued after the termination of the STELLAR trials.

The drugs were generally well-tolerated as monotherapies and dual combination regimens in the Atlas study. The most common adverse events with firsocostat plus cilofexor were mild to moderate pruritus, headache, diarrhoea and nausea.

Gilead Sciences chief medical officer Merdad Parsey said: “NASH is a complex disease driven by multiple mechanisms. The results from the Atlas study suggest the potential for a combination therapeutic approach for patients with advanced fibrosis by targeting different aspects of this disease.

“We continue to analyse the Atlas data and will work with regulators to determine appropriate next steps for these therapies.”

Gilead is also evaluating cilofexor and firsocostat in combination with Novo Nordisk’s GLP-1 analogue semaglutide to treat NASH patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena